about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
23.78
-0.90
(-3.65%)
2.1M
XNAS Volume
XNAS 03 Nov, 2025 4:30 PM (EST)
Board Meeting
The next board meeting for Immunovant Inc is on 10 Nov 2025 for the purpose of Immunovant Inc Second Quarter Earnings Results for 2026
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..